(NASDAQ: CING) Cingulate's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 47.92%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.93%.
Cingulate's earnings in 2025 is -$17,955,009.On average, 7 Wall Street analysts forecast CING's earnings for 2025 to be -$19,571,142, with the lowest CING earnings forecast at -$21,111,005, and the highest CING earnings forecast at -$16,537,964. On average, 7 Wall Street analysts forecast CING's earnings for 2026 to be -$12,907,785, with the lowest CING earnings forecast at -$17,716,270, and the highest CING earnings forecast at -$7,331,262.
In 2027, CING is forecast to generate -$3,091,633 in earnings, with the lowest earnings forecast at -$5,675,572 and the highest earnings forecast at -$284,157.